• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLGN alert in real time by email

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the gene variant present in about 60% of T1D patients.

    “Jonathan brings a strong corporate development and drug development perspective to our team as we position our technology platform towards multiple autoimmune conditions,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. “He is a great asset to the company as we complete Phase 1 studies in T1D, prepare for Phase 2 through early next year, and build our pipeline in celiac disease and other autoimmune diseases.”

    Mr. Rigby has three decades of experience building biopharmaceutical companies from early stages to IPO and acquisitions. He is currently President and Group CEO and a member of the Board of Immune Regulation Ltd, a company involved in developing novel treatments for autoimmune and allergic diseases. Previously, he established SteadyMed Therapeutics Inc, (NASDAQ IPO 2015, STDY), acquired by United Therapeutics (Nasdaq: UTHR) in 2018, and Zogenix, Inc. (NASDAQ IPO 2010, ZGNX). Prior to Zogenix, he worked at Aradigm Corp, a leader in the development of inhaled insulin, and held commercial and business development positions at Merck, Bristol Myers Squibb and Phillips Medical.

    Mr. Rigby currently serves on the Board of Directors of Thermalin Inc., and previously Xeris Pharmaceuticals (Nasdaq: XERS); and Chairman of CollPlant Biotechnologies, (Nasdaq: CLGN). He holds a Bachelor of Science Degree, with Honors, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.

    “I have a deep connection with autoimmune disease management, particularly type 1 diabetes, and am fascinated with the oral targeted drug approach of IM Therapeutics directed at genetic targets,” said Mr. Rigby. “I am also impressed by the clinical progress the team has achieved with IMT-002 as a lead drug in a short period of time and in the midst of a pandemic.”

    About IMT-002

    IMT-002, the lead drug candidate of IM Therapeutics, is the first oral genetically targeted drug candidate to be tested in T1D patients, an incurable autoimmune disorder that affects nearly 1.6 million people in the United States. IMT-002 completed a Phase 1a study in August 2020 and is currently recruiting patients in a Phase 1b study in T1D preselected for the HLA-DQ8 gene variant. IMT-002 has been developed as a selective HLA-DQ8 blocker based on extensive computational work, in vitro and in vivo characterization. Previous studies of a tool drug, L-methyldopa, which is FDA-approved for treating hypertension, in a Phase 1b study, showed effective inhibition of DQ8 activity in new onset type 1 diabetes patients who had the DQ8 gene variant. Several in vivo IND studies indicate that IMT-002, which unlike the tool drug, is not metabolized physiologically, has more potency to block DQ8 activity and a favorable safety profile.

    About IM Therapeutics

    IM Therapeutics (http://imtherapeutics.com/) is a clinical stage company developing personalized medicines for autoimmune diseases by creating oral medicines against human leukocyte antigen (HLA) variants known to confer high risk of disease. The Company’s technology platform develops small molecule drugs using in silico docking of millions of compounds into pockets of an HLA variant where self-antigens may bind to trigger autoimmunity. Selected drug hits are then optimized using proprietary structure-based design and activity screening with cell-based assays for specificity of HLA inhibition. Lead drugs developed against an HLA variant have the ability to block a series of self-antigens and therefore the potential to treat several autoimmune indications related to a selected HLA. The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus.

    Get the next $CLGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLGN
    $UTHR
    $XERS

    CompanyDatePrice TargetRatingAnalyst
    United Therapeutics Corporation
    $UTHR
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    United Therapeutics Corporation
    $UTHR
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    Xeris Biopharma Holdings Inc.
    $XERS
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    United Therapeutics Corporation
    $UTHR
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    Xeris Biopharma Holdings Inc.
    $XERS
    3/28/2024$5.00Outperform
    Oppenheimer
    United Therapeutics Corporation
    $UTHR
    2/12/2024$213.00 → $215.00Sell → Neutral
    Goldman
    United Therapeutics Corporation
    $UTHR
    2/5/2024$330.00Outperform
    Leerink Partners
    United Therapeutics Corporation
    $UTHR
    12/8/2023$309.00Overweight
    Wells Fargo
    More analyst ratings

    $CLGN
    $UTHR
    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

      REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise pr

      5/30/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  REHOVOT, Israel, May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained discip

      5/28/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • Xeris Announces Details for Analyst & Investor Day

      Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for its first in-person and virtual analyst and investor day in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EST. The event will feature key opinion leaders (KOLs) Antonio C. Bianco, MD, PhD (University of Texas Medical Branch), Francesco S. Celi, MD, MHSc (UConn Health), and Eliza B. Geer, MD (Memorial Sloan Kettering Cancer Center), who will join company management to di

      5/20/25 7:30:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    SEC Filings

    See more
    • SEC Form SD filed by United Therapeutics Corporation

      SD - UNITED THERAPEUTICS Corp (0001082554) (Filer)

      5/30/25 4:30:38 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/30/25 7:09:50 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/28/25 7:43:52 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    $UTHR
    $XERS
    Financials

    Live finance-specific insights

    See more
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

      REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

      5/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

      Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X

      2/24/25 8:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Announces CEO Succession Plan

      John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20

      7/8/24 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/13/24 4:15:08 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/12/24 6:28:50 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schmid John P. bought $10,314 worth of shares (5,400 units at $1.91) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      5/10/24 4:04:26 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • United Therapeutics downgraded by Wells Fargo

      Wells Fargo downgraded United Therapeutics from Overweight to Equal Weight

      4/25/25 8:31:30 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • United Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded United Therapeutics from Underperform to Neutral and set a new price target of $314.00

      4/21/25 8:09:51 AM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

      11/11/24 7:52:12 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $129.00 and sold $3,476,765 worth of shares (11,000 units at $316.07) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/30/25 4:30:41 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & GENERAL COUNSEL Mahon Paul A exercised 11,000 shares at a strike of $117.76 and sold $3,246,150 worth of shares (11,000 units at $295.10) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/20/25 4:32:10 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Tommy G exercised 2,500 shares at a strike of $175.43 and sold $762,865 worth of shares (2,500 units at $305.15) (SEC Form 4)

      4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

      5/12/25 4:30:23 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLGN
    $UTHR
    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      11/8/24 4:30:29 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by United Therapeutics Corporation

      SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      10/16/24 1:03:48 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

      SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

      6/10/24 12:15:17 PM ET
      $UTHR
      Biotechnology: Pharmaceutical Preparations
      Health Care